Switching from Ozempic to Wegovy

Why consider switching

Ozempic and Wegovy are both semaglutide. The most common reason to switch is FDA-approved indication: Wegovy is approved specifically for weight management at the 2.4mg maintenance dose, while Ozempic's maximum dose is 2mg and its indication is type 2 diabetes. Patients using Ozempic off-label for weight loss often switch to Wegovy when their insurance starts covering it for weight loss, when supply normalizes, or when their clinician wants to escalate to the full 2.4mg dose used in weight-loss trials.

What changes

Active ingredient stays the same — semaglutide. What changes: the maximum dose available (2mg Ozempic vs 2.4mg Wegovy), the injection device (different pen design), the FDA-approved indication, and often the insurance coverage. Side-effect profile is identical at equivalent doses; the 2.4mg Wegovy maintenance dose may produce more GI side effects simply because it's a higher dose than Ozempic's maximum.

Dose conversion

If on Ozempic 1mg weekly, the standard Wegovy transition is to start at the equivalent Wegovy maintenance step (1mg) and titrate up to 2.4mg over 8-12 weeks. If on Ozempic 0.5mg, start at Wegovy 0.5mg and follow the standard titration. Some clinicians hold at intermediate Wegovy doses (1mg or 1.7mg) if those control appetite well. Your clinician sets the actual schedule.

Transition timeline

1. 1
   Week 0

   Finish your current Ozempic supply; clinician sends Wegovy prescription.

2. 2
   Weeks 1-4

   Start Wegovy at dose equivalent to or one step above your Ozempic dose. Monitor GI tolerance.

3. 3
   Weeks 5-12

   Titrate every 4 weeks per Wegovy schedule toward 2.4mg maintenance, unless side effects warrant a slower pace.

4. 4
   Week 16+

   Steady state on chosen maintenance dose. Schedule clinical follow-up for weight, A1c, side-effect review.

What to watch for

• ·Worse nausea or GI side effects than on Ozempic — often resolves within 2-4 weeks of each dose step
• ·Hypoglycemia if you're also on diabetes medications (sulfonylureas, insulin)
• ·Pancreatitis warning signs: severe abdominal pain radiating to the back
• ·Gallbladder symptoms with significant weight loss

Cost impact

Wegovy list price (~$1,349/mo) is typically higher than Ozempic (~$900-1,000/mo). For diabetes patients with insurance, Ozempic is usually cheaper. For weight-loss patients without diabetes coverage, Wegovy may be MORE affordable because its FDA-approved indication for obesity can unlock weight-loss benefits that Ozempic (diabetes-only) can't. NovoCare self-pay program for Wegovy is ~$499/mo if eligible.